Citigroup Initiates Coverage on Ligand Pharmaceuticals Incorporated (LGND) with Buy
Rating Change Citigroup analysts initiated coverage on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) with a Buy rating on July 21, 2026. Market Context Ligand Pharmaceuticals…
Read more
